6 Epilepsy Clinical Trials in Tucson, AZ (2026)

Q: How do I join a clinical trial in Tucson?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you.

Recruiting Epilepsy Studies in Tucson

NCT05121324Recruiting

Pediatric Dose Optimization for Seizures in Emergency Medical Services

The Pediatric Dose Optimization for Seizures in Emergency Medical Services (PediDOSE) study is designed to improve how paramedics treat seizures in children on ambulances. Seizures are one of the most...

Tucson, AZPHASE36,700 participantsStanford University

View Study Details

NCT06907173Recruiting

Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)

The goal of this clinical trial is to determine if treatment of patients with two doses of ketamine plus levetiracetam versus levetiracetam alone leads to more effective control of status epilepticus....

Tucson, AZPHASE3770 participantsUniversity of Virginia

View Study Details

NCT06132893Recruiting

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy....

Tucson, AZPHASE2390 participantsBiohaven Therapeutics Ltd.

View Study Details

NCT05667142Recruiting

A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of XEN1101 administered as adjunctive treatment in primar...

Tucson, AZPHASE3160 participantsXenon Pharmaceuticals Inc.

View Study Details

NCT05135091Recruiting

FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilate...

Tucson, AZPHASE388 participantsNeurona Therapeutics

View Study Details

NCT07051629Recruiting

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SIF001 in Healthy Subjects and in Epilepsy Patients

This is a dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SIF001, a monoclonal antibody with the potential to treat epilespy...

Tucson, AZPHASE188 participantsSuninflam Inc

View Study Details

About Epilepsy Clinical Trials in Tucson

Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. It affects about 50 million people worldwide. Treatment includes antiseizure medications, surgery, and neurostimulation devices.

There are currently 6 epilepsy clinical trials recruiting participants in Tucson, AZ. These studies are seeking a combined 8,196 participants. Research is being sponsored by Stanford University, University of Virginia, Biohaven Therapeutics Ltd. and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Epilepsy Clinical Trials in Tucson — FAQ

Are there epilepsy clinical trials in Tucson?

Yes, there are 6 epilepsy clinical trials currently recruiting in Tucson, AZ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Tucson?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Tucson research site will contact you about next steps.

Are clinical trials in Tucson free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Tucson studies also compensate for your time and travel.

What epilepsy treatments are being tested?

The 6 active trials in Tucson are testing new therapies including novel drugs, biologics, and treatment approaches for epilepsy.

Data updated July 18, 2026 from ClinicalTrials.gov